MD Anderson Cancer Center reported preclinical work on CBT-001-2334, a carbonic anhydrase IX (CAIX/CA9)-targeted PET tracer designed for gallium labeling and potential therapeutic isotope pairing. The findings focus on translating CAIX biology into imaging utility for cancer settings where tumor hypoxia and CAIX expression can provide clinically actionable stratification.